We are live on ! Find out more
ABUS icon

Arbutus Biopharma
ABUS

55 hedge funds and large institutions have $212M invested in Arbutus Biopharma in 2015 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 17 increasing their positions, 14 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

62% more call options, than puts

Call options by funds: $1.4M | Put options by funds: $864K

21% more repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 14

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

13% less funds holding

Funds holding: 63 → 55 (-8)

39% less first-time investments, than exits

New positions opened: 11 | Existing positions closed: 18

52% less capital invested

Capital invested by funds: $442M → $212M (-$230M)

Holders
55
Holders Change
-8
Holders Change %
-12.7%
% of All Funds
1.54%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
11
Increased
17
Reduced
14
Closed
18
Calls
$1.4M
Puts
$864K
Net Calls
+$537K
Net Calls Change
-$571K

Top Buyers

1
Primecap Management
Primecap Management
California
+$6.72M
2
HM
HealthCor Management
New York
+$3.77M
3
SM
Sabby Management
Florida
+$3.72M
4
Citadel Advisors
Citadel Advisors
Florida
+$3.52M
5
Axa
Axa
France
+$3.33M

Top Sellers

1
BRC
Blue Ridge Capital
New York
-$20.2M
2
RIM
RS Investment Management
California
-$11.5M
3
Bank of Montreal
Bank of Montreal
Ontario, Canada
-$9.2M
4
Invesco
Invesco
Georgia
-$5.1M
5
AC
Ascend Capital
California
-$4.39M
Name Holding Trade Value Shares
Change 		Change in
Stake
QF
1
QVT Financial
New York
$97.5M – – –
Primecap Management
2
Primecap Management
California
$17.3M +$6.72M +758,000 +36%
AWG
3
Alpha Wave Global
New York
$15.9M – – –
HM
4
HealthCor Management
New York
$13.1M +$3.77M +425,000 +25%
Franklin Resources
5
Franklin Resources
California
$12.5M – – –
D.E. Shaw & Co
6
D.E. Shaw & Co
New York
$11.3M -$1.4M -157,536 -8%
Millennium Management
7
Millennium Management
New York
$8.26M -$63.7K -7,186 -0.5%
Axa
8
Axa
France
$4.86M +$3.33M +375,974 +89%
Citadel Advisors
9
Citadel Advisors
Florida
$4.6M +$3.52M +397,242 +111%
SM
10
Sabby Management
Florida
$4.42M +$3.72M +419,656 +137%
Goldman Sachs
11
Goldman Sachs
New York
$4.29M -$612K -68,993 -9%
SFM
12
Sphera Funds Management
Israel
$3.08M +$2.22M +250,000 +98%
SCM
13
Suffolk Capital Management
New York
$1.42M +$228K +25,677 +12%
B
14
Bailard
California
$1.31M +$674K +76,000 +55%
MIG
15
Mariner Investment Group
New York
$1.23M – – –
CS
16
Credit Suisse
Switzerland
$1.11M +$323K +36,470 +25%
BBA
17
Baker Bros. Advisors
New York
$1.1M – – –
CS
18
Candriam SCA
Luxembourg
$1.02M -$128K -14,400 -8%
Deutsche Bank
19
Deutsche Bank
Germany
$927K +$969K +109,300 +254%
Morgan Stanley
20
Morgan Stanley
New York
$774K +$246K +27,758 +28%
BAMS
21
Bellevue Asset Management (Switzerland)
Switzerland
$761K – – –
Renaissance Technologies
22
Renaissance Technologies
New York
$671K +$976K +110,100 New
Group One Trading
23
Group One Trading
Illinois
$478K +$89.8K +10,125 +15%
SIA
24
Sit Investment Associates
Minnesota
$434K – – –
Royal Bank of Canada
25
Royal Bank of Canada
Ontario, Canada
$428K +$19.9K +2,240 +3%
1
2 3

ABUS Hedge Fund Activity: Q3 2015 in Review

55 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in Arbutus Biopharma (ABUS) for Q3 2015, worth a combined $212M — down 52% from $442M a quarter earlier.

Sellers outnumbered buyers: 18 funds closed out of ABUS and 11 opened new positions — a net loss of 7 holders — while 14 trimmed existing stakes and 17 added.

The largest buyer was Primecap Management, adding an estimated $6.72M. The largest seller was Blue Ridge Capital, exiting entirely with an estimated $20.2M sold.

  • 55 institutional investors held Arbutus Biopharma (ABUS) as of Q3 2015, down from 63 in Q2 2015.
  • Funds reported $212M of Arbutus Biopharma stock for Q3 2015, down 52% quarter-over-quarter.
  • 11 funds opened new Arbutus Biopharma positions in Q3 2015 and 18 closed out, a net change of -7 holders.
  • The largest Arbutus Biopharma buyer in Q3 2015 was Primecap Management, an estimated $6.72M added.
  • The largest Arbutus Biopharma seller in Q3 2015 was Blue Ridge Capital, an estimated $20.2M sold.

Based on aggregated 13F filings for Q3 2015.